Shares of BTG plc (LON:BTG) have received an average recommendation of “Buy” from the seven ratings firms that are covering the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is GBX 820 ($10.24).

Several analysts have weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of BTG plc in a research report on Friday, September 9th. Jefferies Group reiterated a “buy” rating and issued a GBX 860 ($10.74) price objective on shares of BTG plc in a research report on Wednesday, November 16th. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 865 ($10.81) price objective (up previously from GBX 850 ($10.62)) on shares of BTG plc in a research report on Wednesday, November 16th. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 900 ($11.24) price objective on shares of BTG plc in a research report on Tuesday, November 15th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a GBX 640 ($8.00) price objective on shares of BTG plc in a research report on Thursday, October 6th.

Shares of BTG plc (LON:BTG) traded up 1.61% during mid-day trading on Friday, hitting GBX 600.00. 560,570 shares of the stock traded hands. BTG plc has a 52 week low of GBX 554.97 and a 52 week high of GBX 739.50. The stock’s market cap is GBX 2.30 billion. The firm’s 50-day moving average is GBX 655.54 and its 200-day moving average is GBX 650.14.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/25/btg-plc-btg-given-consensus-recommendation-of-buy-by-analysts.html.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.